Long-term efficacy and safety of rituximab in the treatment of neuromyelitis Optica Spectrum disorder.

Whilst the post-rituximab ARR was lower without patient 26 (ARR 0.133 [95% CI: 0.043–0.311] vs 0.278 [95% CI: 0.139–0.497] with patient 26), the change from pre-rituximab ARR did not reach statistical significance (pre-rituximab ARR 0.314 [95% CI: 0.157–0.562] without patient 26 vs 0.339 [95% CI: 0.175–0.592] with patient 26; p = 0.313 and 0.432, respectively).

also in 111,027 other papers